Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002663 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
A Phase 1 study of EBV-induced Lymphomas and EBV-associated Malignancies, sponsored by Atara Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT00002663: Completed Phase 1 study of EBV-induced Lymphomas and EBV-associated Malignancies, sponsored by Atara Biotherapeutics.
NCT00002663 is a Phase 1 study of EBV-induced Lymphomas and EBV-associated Malignancies that has completed, run by Atara Biotherapeutics. The registered enrollment target is 58 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002663, a Phase 1 study of EBV-induced Lymphomas and EBV-associated Malignancies, has completed, sponsored by Atara Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
Primary Outcome
The ORR is defined as percentage of participants with best overall response of complete remission/response (CR) or partial remission/response (PR) based on investigator's assessment. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR is complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of the affected tissues when indicated, lasting for at least 3 weeks following completion of a cycle of tabelecleucel; and PR is a
Conditions Studied
Interventions
- BIOLOGICAL Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 1995-03 |
| Est. Completion | 2019-07 |
| Phase | Phase 1 |
What the finished NCT00002663 record still lists
NCT00002663 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 3 conditions, with EBV-induced Lymphomas appearing as the primary indexed condition, and to 1 intervention - of which Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) is the first listed.
NCT00002663 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00002663 about?
NCT00002663 is a clinical study titled "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies". The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
What is the current status of trial NCT00002663?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 1995-03. Estimated completion is 2019-07.
What conditions does trial NCT00002663 study?
This clinical trial studies the following conditions: EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma.
What interventions are being tested in trial NCT00002663?
The interventions under investigation include: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002663?
This trial is sponsored by Atara Biotherapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002663 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002663's enrollment target sits among peer trials
58 895th of 2000 higher than 1,100 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia